Clinical Trial Update: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis [Phase 1]

View source ↗

Summary

This Phase 1 study of JNJ-79635322 in relapsed or refractory multiple myeloma and previously treated AL amyloidosis is currently recruiting. The trial is sponso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Multiple Myeloma

Drugs mentioned

• JNJ-79635322

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis | Phase 1 | Status: RECRUITING